Clinical trials: Rivaroxaban
Covid19, Venous Thromboembolism
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
- Trial name
- MICHELLE (NCT04662684)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- Science Valley Research Institute
Embolism and Thrombosis, Anticoagulation
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation…
- Trial name
- NCT06209892
- Testing
- Extended anticoagulation
- Volunteers
- 220 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Thromboembolic Disorders
A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
Researchers were looking for another way to treat people with a blood clot in their veins. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it behaves.
- Trial name
- NCT04720092
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Atrial Fibrillation
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
The DaRe2 approach (healthcare Data for pragmatic clinical Research in the NHS - primary 2 secondary) is designed to operationalise efficient, nationwide, primary care approaches for randomised trials embedded within the UK…
- Trial name
- DaRe2THINK (NCT04700826)
- Testing
- Direct Oral Anticoagulants
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University of Birmingham
Venous Thromboembolism
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
- Trial name
- EPICT (NCT04066764)
- Testing
- Rivaroxaban, Warfarin, Nadroparin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Antiphospholipid Antibody Syndrome
Rivaroxaban for Antiphospholipid Antibody Syndrome
The antiphospholipid antibody syndrome (APS) is a syndrome associated with excessive blood clotting (thrombosis). APS is among the most common cause of heart attack and stroke in patients under the age of 50 and is particularly…
- Trial name
- RAPS (NCT02116036)
- Testing
- Rivaroxaban
- Where
- 6 sites in Canada
- Volunteers
- 81 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Atrial Fibrillation
Low-dose NOAC Versus GDMT After LAAO
The increased risk of Atrial fibrillation (AF) regarding thromboembolic stroke is predominantly due to the formation and embolization of clots from within the left atrial appendage (LAA).
- Trial name
- RECORD-III (NCT05960721)
- Testing
- Rivaroxaban 15mg, Aspirin 100mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 4,220 people
- Sponsor
- Xijing Hospital
Anticoagulation
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine…
- Trial name
- RE-FIT (NCT02921126)
- Where
- Italy
- Volunteers
- 9,914 people
- Sponsor
- Bristol-Myers Squibb
Anticoagulant Therapy
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation.
- Trial name
- PHAPOCU (NCT05491460)
- Testing
- Apixaban 5 MG Tab, Dabigatran 150 MG Tab, Edoxaban 60Mg Tab
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Doasense GmbH
Venous Thromboembolism, Cancer
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).
- Trial name
- NCT02583191
- Testing
- Rivaroxaban, low-molecular heparine
- Where
- Germany
- Volunteers
- 246 people
- Sponsor
- AIO-Studien-gGmbH
Atrial Fibrillation
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).
- Trial name
- NCT02792335
- Testing
- apixaban, dabigatran, rivaroxaban
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
STEMI - ST Elevation Myocardial Infarction
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition.
- Trial name
- NCT06013020
- Testing
- NOAC+DAPT, DAPT
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Zunyi Medical College
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
AORTIC VALVE DISEASES, Thromboembolism
Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
This study evaluates the long-term anticoagulation with oral factor Xa inhibitor versus vitamin K antagonist in patients receiving a mechanical aortic valve replacement.
- Trial name
- RENOVATE (NCT04258488)
- Testing
- Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin)
- Where
- 16 sites in South Korea
- Volunteers
- 1,300 people
- Sponsor
- Joon Bum Kim
Bleeding Post Cardiac Surgery, Indication for Anticoagulation
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with…
- Trial name
- DANCE (NCT04284839)
- Testing
- DOAC, VKA
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- Population Health Research Institute
Non-valvular Atrial Fibrillation (NVAF)
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.
- Trial name
- NCT01598051
- Testing
- Rivaroxaban (Xarelto_ BAY59-7939)
- Where
- Japan
- Volunteers
- 741 people
- Sponsor
- Bayer
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Venous Thromboembolism, Cancer
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
- Trial name
- TRIM-Line (NCT05029063)
- Testing
- Rivaroxaban 10 MG
- Where
- 11 sites in Canada
- Volunteers
- 1,828 people
- Sponsor
- Ottawa Hospital Research Institute